The role of PSA density in the MRI pathway for prostate cancer diagnostics

Cash, Hannes; Schostak, Martin

doi:10.1038/s41391-022-00579-6

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, since multi-parametric magnetic resonance imaging (mpMRI) of the prostate has become more accessible worldwide, the evaluation of men with elevated PSA levels and clinical suspicion of prostate cancer, and, thus, the decision to perform a prostate biopsy, has drastically changed. Therefore, this imaging technique has begun to play a crucial role in the PCa diagnostic pathway [3][4][5][6]. European Guidelines on Prostate Cancer strongly recommend performing an MRI before a prostate biopsy both in the biopsy-naïve subset and in patients with a prior negative biopsy, in order to subsequently perform a prostate biopsy in men with radiological suspicion of PCa [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Residents and Consultants Have Equal Outcomes When Performing Transrectal Fusion Biopsies: A Randomized Clinical Trial

Turchi,

Lombardo,

Franco

et al. 2024

Current Oncology

View full text Add to dashboard Cite

The aim of our study was to compare the performance of residents vs. consultants in transrectal fusion prostate biopsies (FUS-PBs), as well as patient-reported comfort. Between January 2021 and October 2022, a consecutive series of patients undergoing FUS-PBs were randomized into two groups: (A) FUS-PBs performed by a consultant; (B) FUS-PBs performed by trained residents (>50 procedures). All patients underwent FUS-PBs with 12 systematic cores and 3/6 target cores. The detection rate and number of positive cores in the target lesion were compared between groups, and the patient’s discomfort after the procedure was evaluated using the VAS scale. Overall, 140 patients with a median age of 72 years were enrolled. Overall, 69/140 (49.3%) presented prostate cancer and 53/69 (76.8%) presented a clinically significant cancer (Grade Group ≥ 2). Consultants presented a detection rate of 37/70 (52.9%) and residents a detection rate of 32/70 (45.7%) (p > 0.2); the mean number of positive cores in the index lesion was similar in both groups (1.5 vs. 1.1; p > 0.10). In terms of the patients’ experiences, the procedure was well tolerated, with a median VAS score of 2 in both groups, with no statistically significant differences. Residents showed satisfactory outcomes in terms of detection rate, procedural time, and patient comfort when performing prostate biopsies. Residents, after adequate training, can safely perform prostate biopsies.

show abstract